Pure Global

A Study to Evaluate Available Treatment Information of Ponatinib, Bosutinib, Imatinib, Dasatinib and Nilotinib in Adults With Chronic Myeloid Leukemia - Trial NCT05743465

Access comprehensive clinical trial information for NCT05743465 through Pure Global AI's free database. This phase not specified trial is sponsored by Takeda and is currently Completed. The study focuses on Leukemia. Target enrollment is 1769 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT05743465
Completed
other
Trial Details
ClinicalTrials.gov โ€ข NCT05743465
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Study to Evaluate Available Treatment Information of Ponatinib, Bosutinib, Imatinib, Dasatinib and Nilotinib in Adults With Chronic Myeloid Leukemia
Evaluate the Real-World Safety Outcomes and Clinical Efficacy of Ponatinib and Other Tyrosine Kinase Inhibitors Among Chronic Myeloid Leukemia Patients

Study Focus

Leukemia

No Intervention

Observational

other

Sponsor & Location

Takeda

Cambridge, United States of America

Timeline & Enrollment

N/A

Oct 06, 2021

Nov 30, 2022

1769 participants

Primary Outcome

Number of Chronic Myeloid Leukemia (CML) Participants Categorized by Sociodemographic Variables at Diagnosis,Number of CML Participants With Baseline Clinical Characteristics of Disease Severity,Quan-Charlson Comorbidity Index Score,Number of CML Participants With Baseline Clinical Characteristics of Comorbidities,Number of CML Participants With Baseline Clinical Characteristics of Concomitant Medication,Number of Previous Treatments of Tyrosine Kinase Inhibitors (TKI) Drugs in Participants with CML,Duration Between Last TKI Run-out Date to the Index Date for Participants with CML,Number of Participants with Bone Marrow Stem Cell Transplant,Clinical Characteristics Assessed by Number of Participants With Major Adverse Cardiac Events (MACE), Arterial Occlusive Events (AOEs), and Venous Thrombotic Events (VTEs),Treatment Patterns Based on Duration of Index Treatment

Summary

The aims of this study are to learn out about treatment information (including amongst others
 treatment patterns, safety, development of a participant's condition) ponatinib, bosutinib,
 imatinib, dasatinib and nilotinib using already available data. No new data will be collected
 from participants as part of this study and no study medicines will be provided in this
 study.

ICD-10 Classifications

Leukaemia, unspecified
Myeloid leukaemia
Myeloid leukaemia, unspecified
Other myeloid leukaemia
Monocytic leukaemia, unspecified

Data Source

ClinicalTrials.gov

NCT05743465

Non-Device Trial